One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
The usefulness of serum leucine-rich alpha-2 glycoprotein as a novel biomarker in monitoring inflammatory bowel disease: a systematic review and meta-analysis.
doi : 10.1097/MEG.0000000000002952
Volume 37(8) pgs. 891-991 August 2025
Autoimmune chronic atrophic gastritis: association between chronic proton pump inhibitors use and more severe atrophy and gastric intestinal metaplasia.
The impact of ethnicity on delays in initiating advanced therapy for inflammatory bowel disease.
Psychological symptoms and alexithymia in adolescents with inflammatory bowel diseases: a case-control study.
Cytomegalovirus infection in patients with active ulcerative colitis: a prospective observational study.
Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey.
Nomogram model for identifying portal vein thrombosis in patients with decompensated cirrhosis.
Noninvasive prediction model for predicting spontaneous tumor necrosis in hepatocellular carcinoma and prognostic study.
Combination of fibrosis-4 score and D-dimer: a practical approach to identify poor outcome in COVID-19.
Enhancing diagnostic accuracy for HBV-related cirrhosis progression: predictive modeling using combined Golgi protein 73 and [alpha]1-microglobulin for the transition from nondecompensated to decompensated cirrhosis.
Evaluation of the incidence and risk factors for the development of acute-on-chronic liver failure in outpatients with cirrhosis.
Heterogeneity of cardiometabolic and hepatic fibrosis risks in nonalcoholic fatty liver disease among lean, overweight, and obese populations: a multicenter cross-sectional study.
Hepatotoxicity associated with vedolizumab: case report in a patient with ulcerative colitis.
Letter to the editor regarding 'First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn's disease'.
